Clinical Trials Logo

Citation(s)

Bone Marker-directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma.

Details for clinical trial NCT00622505